Nevirapine Once Daily is Moving Further Steps
Nevirapine Once Daily is Moving Further Steps
Sari Arponen
NULL
*Correspondence: Sari Arponen, Email not available
Abstract
Two trials are currently ongoing in drug-naiveHIV‑infected individuals in which the safety and efficacyof nevirapine 400 mg once daily is re-assessed.ARTEN (atazanavir, ritonavir, tenofovir, emtricitabineand nevirapine) is a prospective, international, openlabel,randomized study in which 561 drug-naiveHIV-positive individuals will be allocated to receiveone of the following three arms: atazanavir/ritonavirtwice daily, nevirapine twice daily, or nevirapineonce daily, in all instances along with Truvada®(tenofovir plus emtricitabine).
